HRP20211877T1 - Spojevi n-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamida i n-(4-hidroksi-4-metil-cikloheksil)-4- (2-piridil)-benzensulfonamida i njihova terapijska uporaba - Google Patents
Spojevi n-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamida i n-(4-hidroksi-4-metil-cikloheksil)-4- (2-piridil)-benzensulfonamida i njihova terapijska uporaba Download PDFInfo
- Publication number
- HRP20211877T1 HRP20211877T1 HRP20211877TT HRP20211877T HRP20211877T1 HR P20211877 T1 HRP20211877 T1 HR P20211877T1 HR P20211877T T HRP20211877T T HR P20211877TT HR P20211877 T HRP20211877 T HR P20211877T HR P20211877 T1 HRP20211877 T1 HR P20211877T1
- Authority
- HR
- Croatia
- Prior art keywords
- solvate
- hydrate
- salt
- compound
- treatment
- Prior art date
Links
- ZLVPOPZOUSJLFL-UHFFFAOYSA-N n-(4-hydroxy-4-methylcyclohexyl)-4-phenylbenzenesulfonamide Chemical compound C1CC(C)(O)CCC1NS(=O)(=O)C1=CC=C(C=2C=CC=CC=2)C=C1 ZLVPOPZOUSJLFL-UHFFFAOYSA-N 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 17
- 239000012453 solvate Substances 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 206010065687 Bone loss Diseases 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010066476 Haematological malignancy Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000010029 ameloblastoma Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000000270 basal cell Anatomy 0.000 claims 1
- 208000016738 bone Paget disease Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000002997 osteoclast Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Claims (17)
1. Spoj, naznačen time, da ima sljedeću formulu, ili njegova farmaceutski prihvatljiva sol, hidrat ili solvat:
[image]
2. Farmaceutski pripravak, naznačen time, da sadrži spoj, sol, hidrat ili solvat u skladu s patentnim zahtjevom 1, i farmaceutski prihvatljiv nosač ili razrjeđivač.
3. Postupak za pripravu farmaceutskog pripravka, naznačen time, da obuhvaća korak miješanja spoja, soli, hidrata ili solvata u skladu s patentnim zahtjevom 1, s farmaceutski prihvatljivim nosačem ili razrjeđivačem.
4. Spoj, sol, hidrat ili solvat za uporabu u skladu s patentnim zahtjevom 1, naznačen time, da je za uporabu u postupku liječenja ljudskog ili životinjskog tijela putem terapije.
5. Spoj, sol, hidrat ili solvat za uporabu u skladu s patentnim zahtjevom 4, naznačen time, da služi u postupku liječenja reumatoidnog artritisa.
6. Spoj, sol, hidrat ili solvat za uporabu u skladu s patentnim zahtjevom 4, naznačen time, da služi u postupku liječenja: psorijaze; psorijatičkog artritisa; kronične opstruktivne plućne bolesti; astme; ateroskleroze; upalne bolesti crijeva; ili ankiloznog spondilitisa.
7. Spoj, sol, hidrat ili solvat za uporabu u skladu s patentnim zahtjevom 4, naznačen time, da služi u postupku liječenja: multiple skleroze; sustavnog eritematoznog lupusa; ili Sjögrenovog sindroma.
8. Spoj, sol, hidrat ili solvat za uporabu u skladu s patentnim zahtjevom 4, naznačen time, da služi u postupku liječenja poremećaja povezanog s gubitkom kostiju.
9. Spoj, sol, hidrat ili solvat za uporabu u skladu s patentnim zahtjevom 4, naznačen time, da služi u postupku liječenja: gubitka kostiju povezanog s prekomjernim djelovanjem osteoklasta kod reumatoidnog artritisa, osteoporoze, bolesti kostiju povezane s rakom, ili Pagetove bolesti.
10. Spoj, sol, hidrat ili solvat za uporabu u skladu s patentnim zahtjevom 4, naznačen time, da služi u postupku liječenja raka.
11. Spoj, sol, hidrat ili solvat za uporabu u skladu s patentnim zahtjevom 4, naznačen time, da služi u postupku liječenja hematološke malignosti.
12. Spoj, sol, hidrat ili solvat za uporabu u skladu s patentnim zahtjevom 4, naznačen time, da služi u postupku liječenja: leukemije; ili limfoma.
13. Spoj, sol, hidrat ili solvat za uporabu u skladu s patentnim zahtjevom 4, naznačen time, da služi u postupku liječenja raka čvrstih tumora.
14. Spoj, sol, hidrat ili solvat za uporabu u skladu s patentnim zahtjevom 4, naznačen time, da služi u postupku liječenja: raka mokraćnog mjehura; raka dojke; raka debelog crijeva; karcinoma bubrežnih stanica; raka bubrega; raka pluća; raka gušterače; raka želuca; raka prostate; raka mozga; raka kože; raka štitnjače; ameloblastoma bazalnih stanica; ili melanoma.
15. Spoj, sol, hidrat ili solvat za uporabu u skladu s patentnim zahtjevom 4, naznačen time, da služi u postupku liječenja poremećaja povezanog s fibrozom.
16. Spoj, sol, hidrat ili solvat za uporabu u skladu s patentnim zahtjevom 4, naznačen time, da služi u postupku liječenja sustavne skleroze ili skleroderme.
17. Spoj, sol, hidrat ili solvat za uporabu u skladu s patentnim zahtjevom 4, naznačen time, da služi u postupku liječenja Behçetove bolesti.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201422469 | 2014-12-17 | ||
| PCT/EP2015/080022 WO2016097001A1 (en) | 2014-12-17 | 2015-12-16 | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use |
| EP15810646.8A EP3262028B1 (en) | 2014-12-17 | 2015-12-16 | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(-4hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211877T1 true HRP20211877T1 (hr) | 2022-03-04 |
Family
ID=54850187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211877TT HRP20211877T1 (hr) | 2014-12-17 | 2015-12-16 | Spojevi n-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamida i n-(4-hidroksi-4-metil-cikloheksil)-4- (2-piridil)-benzensulfonamida i njihova terapijska uporaba |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10005733B2 (hr) |
| EP (1) | EP3262028B1 (hr) |
| JP (1) | JP6650942B2 (hr) |
| CN (1) | CN107108508B (hr) |
| AU (1) | AU2015367528B2 (hr) |
| CA (1) | CA2970578C (hr) |
| ES (1) | ES2899852T3 (hr) |
| HR (1) | HRP20211877T1 (hr) |
| HU (1) | HUE057569T2 (hr) |
| LT (1) | LT3262028T (hr) |
| MA (1) | MA41587A (hr) |
| SI (1) | SI3262028T1 (hr) |
| WO (1) | WO2016097001A1 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
| HUE057569T2 (hu) | 2014-12-17 | 2022-05-28 | Pimco 2664 Ltd | N-(4-hidroxi-4-metil-ciklohexil)-4-fenil-benzolszulfonamid és N-(4-hidroxi-4-metil-ciklohexil)-4-(2-piridil)-benzolszulfonamid vegyületek és terápiás alkalmazásuk |
| GB201813312D0 (en) | 2018-08-15 | 2018-09-26 | Modern Biosciences Ltd | Compounds and their therapeutic use |
| GB201905520D0 (en) | 2019-04-18 | 2019-06-05 | Modern Biosciences Ltd | Compounds and their therapeutic use |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB597810A (en) | 1943-04-12 | 1948-02-04 | Gen Printing Ink Corp | Improvements in or relating to derivatives of diphenyl |
| DE1046220B (de) | 1956-04-21 | 1958-12-11 | Bayer Ag | Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen |
| US4119784A (en) | 1977-07-01 | 1978-10-10 | American Cyanamid Company | Anionic substituted sulfonamido biphenyls |
| DE3000519A1 (de) | 1979-02-01 | 1980-08-14 | Byk Gulden Lomberg Chem Fab | Sulfonamido-alkansaeuren, ihre verwendung und herstellung sowie sie enthaltende arzneimittel |
| DE3535167A1 (de) | 1985-10-02 | 1987-04-09 | Boehringer Mannheim Gmbh | Neue sulfonyl-phenyl(alkyl)amine, verfahren zu ihrer herstellung sowie arzneimittel |
| IL118325A0 (en) | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
| EP0934291A1 (en) | 1995-10-30 | 1999-08-11 | Smithkline Beecham Corporation | Protease inhibitors |
| US5760028A (en) | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| WO1997033887A1 (en) | 1996-03-15 | 1997-09-18 | Du Pont Pharmaceuticals Company | Spirocycle integrin inhibitors |
| JP2000515153A (ja) | 1996-07-22 | 2000-11-14 | モンサント カンパニー | チオールスルホンアミド メタロプロテアーゼインヒビター |
| IL129147A0 (en) | 1996-10-16 | 2000-02-17 | American Cyanamid Co | The preparation and use of ortho-sulfonamide aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| AU5362998A (en) | 1996-11-27 | 1998-06-22 | Du Pont Pharmaceuticals Company | Novel integrin receptor antagonists |
| WO1998043962A1 (en) | 1997-03-28 | 1998-10-08 | Du Pont Pharmaceuticals Company | Heterocyclic integrin inhibitor prodrugs |
| PL337755A1 (en) | 1997-05-08 | 2000-09-11 | Smithkline Beecham Corp | Protease inhibitors |
| DE19719621A1 (de) | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
| ATE210639T1 (de) | 1997-05-09 | 2001-12-15 | Hoechst Ag | Substituierte diaminocarbonsäuren |
| US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| SK10632000A3 (sk) | 1998-01-23 | 2001-02-12 | Aventis Pharma Deutschland Gmbh | Sulfónamidové deriváty ako inhibítory resorpcie kostí a inhibítory bunkovej adhézie |
| HUP0101176A3 (en) | 1998-02-04 | 2002-06-28 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them |
| JPH11246527A (ja) | 1998-03-02 | 1999-09-14 | Shionogi & Co Ltd | Ｍｍｐ−８阻害剤 |
| DE19815547C1 (de) | 1998-04-07 | 1999-12-02 | Joachim Schmidt | Haftmittel für Zahnprothesen |
| EP0960882A1 (en) | 1998-05-19 | 1999-12-01 | Hoechst Marion Roussel Deutschland GmbH | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists |
| EP1265886A2 (en) | 2000-03-21 | 2002-12-18 | The Procter & Gamble Company | Carbocyclic side chain containing, n-substituted metalloprotease inhibitors |
| WO2001090077A1 (en) | 2000-05-19 | 2001-11-29 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
| WO2002060867A2 (en) | 2001-01-29 | 2002-08-08 | Insight Strategy And Marketing Ltd | Carbazole derivatives and their uses as heparanase inhibitors |
| US20050119305A1 (en) | 2001-03-21 | 2005-06-02 | Masao Naka | Il-6 production inhibitors |
| WO2002089785A1 (en) | 2001-05-07 | 2002-11-14 | Smithkline Beecham Corporation | Sulfonamides |
| CA2457468A1 (en) | 2001-08-09 | 2003-02-27 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and pharmaceutical agent comprising the same as active ingredient |
| GB0126157D0 (en) | 2001-10-31 | 2002-01-02 | Univ Aberdeen | Therapeutic compounds |
| WO2003080042A1 (fr) | 2002-03-27 | 2003-10-02 | Shionogi & Co., Ltd. | Inhibiteur de decomposition pour matrice extracellulaire de cartilage |
| MXPA05002571A (es) | 2002-09-04 | 2005-09-08 | Schering Corp | Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina. |
| DE10251170A1 (de) | 2002-10-31 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| WO2004073619A2 (en) | 2003-02-14 | 2004-09-02 | Smithkline Beecham Corporation | Ccr8 antagonists |
| US7572825B2 (en) | 2003-05-07 | 2009-08-11 | The University Court Of The University Of Aberdeen | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions |
| WO2004106290A1 (ja) | 2003-05-14 | 2004-12-09 | Kissei Pharmaceutical Co., Ltd. | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 |
| WO2005025554A2 (en) | 2003-09-09 | 2005-03-24 | Japan Tobacco Inc. | Dipeptidyl peptidase iv inhibitor |
| GB0324792D0 (en) | 2003-10-23 | 2003-11-26 | Sterix Ltd | Compound |
| WO2005060963A1 (en) | 2003-12-19 | 2005-07-07 | Pfizer Inc. | Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity |
| US7326732B2 (en) | 2004-02-12 | 2008-02-05 | Pharmagene Laboratories Limited | EP2 receptor agonists |
| GB0405193D0 (en) | 2004-03-08 | 2004-04-21 | Medical Res Council | Compounds |
| US20080255240A1 (en) | 2004-05-05 | 2008-10-16 | Novo Nordisk A/S | Sulfonamide Derivatives |
| GB0412553D0 (en) | 2004-06-04 | 2004-07-07 | Univ Aberdeen | Therapeutic agents for the treatment of bone conditions |
| WO2005123089A2 (en) | 2004-06-10 | 2005-12-29 | Kalypsys, Inc. | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
| RS20070076A (en) | 2004-10-29 | 2008-09-29 | Astrazeneca Ab., | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases |
| EP1659113A1 (en) | 2004-11-08 | 2006-05-24 | Evotec AG | Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) |
| AU2006257646A1 (en) | 2005-06-16 | 2006-12-21 | Pfizer Inc. | N-(pyridin-2-YL)-sulfonamide derivatives |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| TW200720261A (en) | 2005-08-31 | 2007-06-01 | Sankyo Co | Phenylene derivatives |
| HUE032640T2 (en) | 2005-11-08 | 2017-10-30 | Vertex Pharma | Heterocyclic modulator of ATP-binding cassette transcripts |
| CN103265495B (zh) | 2005-12-29 | 2016-11-16 | 莱西肯医药有限公司 | 多环氨基酸衍生物及其使用方法 |
| US7560597B2 (en) | 2007-03-08 | 2009-07-14 | The University Court Of The University Of Aberdeen | 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents |
| GB0705400D0 (en) | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
| WO2010025235A1 (en) | 2008-08-29 | 2010-03-04 | Regents Of The University Of Michigan | Selective ligands for the dopamine 3 (d3) receptor and methods of using the same |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| GB0817208D0 (en) * | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | Therapeutic apsap compounds and their use |
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
| GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
| HUE057569T2 (hu) | 2014-12-17 | 2022-05-28 | Pimco 2664 Ltd | N-(4-hidroxi-4-metil-ciklohexil)-4-fenil-benzolszulfonamid és N-(4-hidroxi-4-metil-ciklohexil)-4-(2-piridil)-benzolszulfonamid vegyületek és terápiás alkalmazásuk |
-
2015
- 2015-12-16 HU HUE15810646A patent/HUE057569T2/hu unknown
- 2015-12-16 AU AU2015367528A patent/AU2015367528B2/en active Active
- 2015-12-16 SI SI201531774T patent/SI3262028T1/sl unknown
- 2015-12-16 WO PCT/EP2015/080022 patent/WO2016097001A1/en active Application Filing
- 2015-12-16 LT LTEPPCT/EP2015/080022T patent/LT3262028T/lt unknown
- 2015-12-16 US US15/534,228 patent/US10005733B2/en active Active
- 2015-12-16 EP EP15810646.8A patent/EP3262028B1/en active Active
- 2015-12-16 HR HRP20211877TT patent/HRP20211877T1/hr unknown
- 2015-12-16 MA MA041587A patent/MA41587A/fr unknown
- 2015-12-16 ES ES15810646T patent/ES2899852T3/es active Active
- 2015-12-16 CA CA2970578A patent/CA2970578C/en active Active
- 2015-12-16 CN CN201580072308.XA patent/CN107108508B/zh active Active
- 2015-12-16 JP JP2017532715A patent/JP6650942B2/ja active Active
-
2018
- 2018-06-19 US US16/011,718 patent/US20180297955A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MA41587A (fr) | 2021-04-28 |
| ES2899852T3 (es) | 2022-03-15 |
| SI3262028T1 (sl) | 2022-02-28 |
| EP3262028B1 (en) | 2021-10-27 |
| AU2015367528B2 (en) | 2020-05-14 |
| CA2970578C (en) | 2024-01-02 |
| EP3262028A1 (en) | 2018-01-03 |
| WO2016097001A1 (en) | 2016-06-23 |
| HUE057569T2 (hu) | 2022-05-28 |
| CN107108508A (zh) | 2017-08-29 |
| CN107108508B (zh) | 2020-09-01 |
| US20170349551A1 (en) | 2017-12-07 |
| US20180297955A1 (en) | 2018-10-18 |
| JP6650942B2 (ja) | 2020-02-19 |
| AU2015367528A1 (en) | 2017-07-13 |
| LT3262028T (lt) | 2022-01-10 |
| CA2970578A1 (en) | 2016-06-23 |
| US10005733B2 (en) | 2018-06-26 |
| JP2018509380A (ja) | 2018-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211877T1 (hr) | Spojevi n-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamida i n-(4-hidroksi-4-metil-cikloheksil)-4- (2-piridil)-benzensulfonamida i njihova terapijska uporaba | |
| HRP20171611T1 (hr) | N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamidi i n-(4-hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamidi i njihova terapeutska primjena | |
| PH12017501339A1 (en) | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof | |
| MX2016010266A (es) | Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso. | |
| WO2015109180A3 (en) | Compositions and methods for treatment and detection of cancers | |
| PH12017500635B1 (en) | Aminopyridyloxypyrazole compounds | |
| JP2017538677A5 (hr) | ||
| JP2016501221A5 (hr) | ||
| JP2016538344A5 (hr) | ||
| TN2016000458A1 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer. | |
| PH12017501989A1 (en) | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient | |
| EA201591686A1 (ru) | Пиридинильные и конденсированные пиридинильные производные триазолона | |
| JP2015512398A5 (hr) | ||
| JP2017520613A5 (hr) | ||
| JP2017514806A5 (hr) | ||
| RU2020102939A (ru) | 17a,21-диэфиры кортексолона для применения в лечении опухолей | |
| JP2016529218A5 (hr) | ||
| EA201492250A1 (ru) | Гетероциклическое соединение | |
| MA43570A (fr) | Thérapie génique pour traiter l'hypercholestérolémie familiale | |
| NZ726790A (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
| MX2017011600A (es) | Terapeuticos de anticuerpo que enlazan antigeno de membrana especifico de prostata. | |
| NZ730160A (en) | Substituted bicyclic compounds | |
| TN2015000356A1 (en) | Bicyclic compounds | |
| JP2018509380A5 (hr) | ||
| EA201791881A1 (ru) | Производные 2-аминопиридина в качестве антагонистов рецептора аденозина aи лигандов рецепторов мелатонина mt |